Using liquid biopsies and breath samples to detect lung cancer mutations
A Prospective, Single Center Study to Test the Validity and Feasibility of Circulating Tumor DNA in Blood, Sputum and Alveolar Fluid, as Well as Exhaled Volatile Organic Compounds as Biomarkers in Non-Small Cell Lung Cancer
This study is testing if using samples from blood, sputum, and breath can help find lung cancer mutations in patients with non-small cell lung cancer before and after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 210 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | St. Joseph's Healthcare Hamilton Academic / other |
| Locations | 1 site (Hamilton, Ontario) |
| Trial ID | NCT06707519 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the feasibility of recruiting participants and utilizing various biological samples, including sputum, bronchoalveolar lavage (BAL), and exhaled volatile organic compounds (VOC), alongside blood, to detect mutations in cell-free DNA in patients with non-small cell lung cancer (NSCLC). The study will follow patients undergoing surgical resection for NSCLC-adenocarcinoma, collecting samples at multiple time points before and after surgery, as well as during follow-up visits over a 24-month period. The goal is to evaluate the potential of these samples as novel biomarkers for monitoring disease recurrence and treatment response.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are undergoing surgical resection with curative intent for NSCLC-adenocarcinoma.
Not a fit: Patients with non-curative surgical resections, metastatic disease, or other malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve early detection of lung cancer recurrence and enhance monitoring of treatment responses.
How similar studies have performed: While the use of ctDNA in blood for cancer detection has shown promise, the validation of sputum and BAL samples for this purpose is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient must be at least 18 years of age * Patient must be able to provide consent * Patients undergoing surgical resection with curative intent for non-small cell lung cancer at St. Joseph's Healthcare Hamilton and Firestone Institute for Respiratory Health. Exclusion Criteria: * Resection done with non-curative intent or metastatic disease * other malignancies * Patients with previously treated malignancy less than 5 years prior to current resection (not including skin cancer).
Where this trial is running
Hamilton, Ontario
- St. Joseph's Healthcare Hamilton — Hamilton, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: Layla Halwagi, BSc
- Email: Lhalwagi@stjosham.on.ca
- Phone: 905-522-1155
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.